Strides Pharma Science Ltd

On a consolidated basis, profit after tax rose 131.14% YoY to Rs 208.12 crore in Q3 FY26 from Rs 90.04 crore a year ago. On a sequential basis, PAT rose 58.24% QoQ from Rs 131.52 crore. Operational profit after tax rose 38.6% YoY to Rs 128.2 crore in Q3 FY26 from Rs 92.5 crore a year ago. On a sequential basis, operational PAT declined 8.6% QoQ from Rs 140.3 crore. Revenue increased 3.6% YoY to Rs 1,194.6 crore in Q3 FY26 compared with Rs 1,153.7 crore in Q3 FY25. Sequentially, revenue declined 2.1% QoQ from Rs 1,220.8 crore. Revenue was impacted by low offtake in the institutional business and flattish US operations. Gross profit rose 8.6% YoY to Rs 731.7 crore from Rs 673.5 crore. Gross margin expanded sharply to 61.2%, an improvement of 280 bps YoY and 340 bps QoQ. EBITDA increased 12.2% YoY to Rs 235.9 crore in Q3 FY26 from Rs 210.3 crore, while rising 1.9% QoQ. EBITDA margin improved to 19.8%, up 160 bps YoY and 80 bps sequentially. Ex-US market revenue stood at $64 million, registering a strong 20% YoY growth. Growth was led by other regulated markets and growth markets, which helped offset weak institutional demand and flat US performance. Management reiterated continued investments in sustainable long-term growth and announced the appointment of Peter Hardwick as CEO of the North America business. Strides Pharma Science is a Bengaluru-headquartered global pharmaceutical company focused on regulated and emerging markets, with manufacturing facilities across India, Italy, Kenya and the US, and a presence in over 100 countries. Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 129.80% to Rs 202.11 crore in the quarter ended December 2025 as against Rs 87.95 crore during the previous quarter ended December 2024. Sales rose 3.55% to Rs 1194.65 crore in the quarter ended December 2025 as against Rs 1153.67 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales1194.651153.67 4 OPM %19.7518.23 - PBDT299.40164.70 82 PBT248.78116.28 114 NP202.1187.95 130 Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live

In an exchange filing, the company said the current Good Manufacturing Practices (cGMP) inspection was conducted by the US Food and Drug Administration (USFDA) at the facility between 17 December and 23 December 2025. At the conclusion of the inspection, the regulator issued a Form 483 containing four observations. The company clarified that the observations are procedural in nature and are not expected to have any impact on the supply of its commercial products. SPI will submit a comprehensive response to the USFDA within the stipulated timeframe and expressed confidence in addressing all the observations to the regulator's satisfaction. Strides Pharma further stated that it will keep the stock exchanges informed of any further developments in this matter. The official announcement was made on 24 December 2025, after market hours. Strides Pharma Science is a global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures a wide range of niche and technically complex pharmaceutical products. The company's consolidated net profit jumped 81.98% to Rs 131.52 crore on a 4.62% increase in revenue from operations to Rs 1,220.83 crore in Q2 Sept 2025 over Q2 Sept 2024. Powered by Capital Market - Live

Strides Pharma Science announced that Puneet Kumar Malik, Senior Management Personnel of the Company has desired to relinquish his position w.e.f. close of business hours on 31 January 2026 to pursue other opportunity within the Aditya Birla Group.Powered by Capital Market - Live

Strides Pharma Science announced that Surabhi Loshali, Group CHRO of the Company, has resigned from Strides to pursue her personal and professional aspirations. Her last working day with Strides shall be closing business hours of 02 January 2026.Powered by Capital Market - Live

Net profit of Strides Pharma Science rose 77.52% to Rs 127.53 crore in the quarter ended September 2025 as against Rs 71.84 crore during the previous quarter ended September 2024. Sales rose 4.62% to Rs 1220.83 crore in the quarter ended September 2025 as against Rs 1166.93 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales1220.831166.93 5 OPM %18.8815.76 - PBDT211.53138.53 53 PBT161.8990.08 80 NP127.5371.84 78 Powered by Capital Market - Live

Profit before tax (PBT) climbed 77.62% YoY to Rs 153.11 crore in Q2 FY26. EBITDA stood at Rs 231.6 crore in Q2 FY26, registering the growth of 25.4% compared with Rs 184.6 crore in Q2 FY25. EBITDA margin improved by 320 bps to 19% in Q2 FY26 as against 15.8% in Q2 FY25. Revenue from the US market rose 2% year-on-year to $73 million in Q2 FY26, while revenue from other regulated markets increased 16% YoY to $44 million during the quarter. Badree Komandur, MD & Group CEO, said, 'Strides continues to deliver a strong performance in Q2FY26, with growth primarily driven by the other regulated markets. Our focus on profitability enabled the gross margin growth of 15% YoY, and EBITDA growth of 25% YoY. Operational PAT stood at Rs 140.3 crore, up 84% YoY, with EPS rising to Rs 15.2 for the quarter. Net debt reduced sequentially by Rs 46.9 crore despite currency headwinds and ongoing capex investments, reaffirming our strong financial discipline and focus on balance sheet health. This performance demonstrates our consistent execution as we continue to invest in sustainable, long-term growth.' Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products.Powered by Capital Market - Live

Strides Pharma Science will hold a meeting of the Board of Directors of the Company on 31 October 2025.Powered by Capital Market - Live

Under the terms of the agreement, Strides will collaborate with Kenox on the development and regulatory filing of multiple nasal spray products for the US market, spanning various therapeutic indications. The partnership aims to leverage Kenox's specialized expertise in OINDPs and Strides' strong presence in regulated markets. 'We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space,' said Aditya Kumar, executive director ' business development, Strides Pharma Science. 'Nasal sprays have consistently been a key focus area for Strides, and this collaboration builds on the solid progress we've already made in this domain. With our continued investments in capabilities and capacities at our US facility, these products are a natural extension of our strategy to grow in the nasal spray technology segment. Kenox's formulation and development strengths perfectly complement our manufacturing and go-to-market capabilities, enabling us to accelerate the expansion of our nasal spray portfolio in the US market.' Dr. Sitaram Velaga, founder, president, and CEO of Kenox Pharmaceuticals Inc., added, 'Our strategic partnership with Strides marks a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and enables us to leverage our capabilities to bring important drug products to patients worldwide at an affordable price.' The partnership aims to advance a pipeline of nasal spray products for the US market, combining Strides' strong commercial presence with Kenox's specialized OINDP expertise to deliver high-quality, affordable therapies to patients. The company's consolidated net profit plunged 96.8% to Rs 105.59 crore in Q1 FY26, compared to Rs 3,349.58 crore reported in Q1 FY25. Meanwhile, net sales increased 6.2% year-on-year to Rs 1,119.47 crore during the quarter. Shares of Strides Pharma Science rose 0.07% to Rs 881.70 on the BSE. Powered by Capital Market - Live